Response Genetics Announces Publication of a Phase III Clinical
Trial Demonstrating That Low Levels of ERCC-1 Help to Predict
Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- Respons
eGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...
TMC125 Showed Significant Virologic Response at Week 24 in
Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3
Data Published in The Lancet on TMC125, an Investigational NNRTIfrom Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from twoongoing Phase 3 studies (DUET-1 and DUET-2) showed significantlymore HIV-1 adult patients with documented non-nucleoside reversetranscriptase inhibitor (NNRTI) and protease inhibitor (PI)resistance reached an undetectable viral load (defined as achievingco...
Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free
Response Across Multiple Attacks
Nearly Twice as Many Patients Taking Trexima were Migraine FreeCompared to Placebo CHICAGO, June 08, 2007 /PRNewswire/ -- New data from two largetrials show that Trexima, when taken early, was nearly twice aseffective as placebo in eliminating all traditional migrainesymptoms at two and four hours across multiple attacks with justone tablet. The findings will be presented tomorrow at the...
Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides
Sustained Immune Response in 100 Percent of Women up to 55 Years of
New Study Results Show Antibodies Against Cancer-Causing VirusTypes 16 & 18 That Are At Least Ten Times Greater Than NaturalInfection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data showthat at 18 months after the first of a three-dose regimen, 100percent of women up to age 55 vaccinated with the GlaxoSmithKline(GSK) cervical cancer candidate vaccine had antibodies pr...
Data Demonstrated Metastatic Melanoma Response to Investigational
Clinical Phase I and II data presented at American Society ofClinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc.and Bristol-Myers Squibb Company today presented results frommultiple clinical studies of ipilimumab (MDX-010), aninvestigational immunotherapy, for patients with advanced melanoma.The results demonstrated an anti-tumor res...
Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in
Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Preliminary Results of Largest Randomized, Placebo-controlled TrialEver Conducted in CTCL Presented at the American Society ofClinical Oncology CHICAGO, June 04, 2007 /PRNewswire/ -- Preliminary results ofthe largest randomized, placebo-controlled clinical trial everconducted in patients with cutaneous T-cell lymphoma (CTCL) showedthat ONTAK was more than twice as effective as placebo in...
Introgen Reports Updated Phase 2 Advexin Data Correlating Improved
Survival, Tumor Responses and Predictive p53 Biomarker
CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.(NASDAQ: INGN) and the Company's clinical collaborators todayreported updated Phase 2 data demonstrating a significantcorrelation between abnormal p53, tumor respons
es and increasedsurvival following ADVEXIN(R) therapy in patients with recurrentsquamous cell carcinoma of the head and neck. The data (Abstract#6057) were prese...
Pharmexa A/S (DK) - Long lasting immune response and survival to
HORSOLM, Denmark, June 4, 2007-Professor Trond Buanes today gavea presentation titled "RAS peptide vaccination in resectedpancreatic cancer patients - persistence of anti tumour respons
eand long term survival" at ASCO's (American Society of ClinicalOncology) annual cancer meeting. A follow-up study of 23 resected pancreatic cancer...
Dasatinib Shows High Early Response Rate as First Treatment for
Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
CHICAGO, June 2, 2007 - An established second-linedrug for chronic myelogenous leukemia has high respons
e rates whengiven to newly diagnosed patients as their first therapy for thedisease, according to early results from a Phase II clinical trialat The University of Texas M. D. Anderson Cancer Center. "Patients taking dasatinib achieve complete cytogenetic respons
e- absence of the...
Inovio Biomedical's DNA Delivery Technology Shows Safety and
Enhances Gene Expression & Tumor Responses in Interim Melanoma
Clinical Study Results
SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-based DNAvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat interim clinical trial results demonstrated that a DNA-basedimmunotherapy delivered by Inovio's electroporation technology wassafe and tole...
CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response
Against Avian Flu Antigen in Animals
VIENNA, Va., May 23, 2007 /PRNewswire-FirstCall/ -- CEL-SCICORPORATION announces that CEL-1000 increased the immune respons
eagainst H5 avian influenza antigen in combination with MAS-1, awater-in-oil adjuvant delivery system. These findings werepresented on May 23, 2007 by Dr. Daniel Zimmerman, Senior VicePresident of Research, Cellular Immunology at CEL-SCI at theAmerican Society of Mic...
VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine
Candidates Trigger Robust Immune Responses and Protection in
MALAGA, Spain--(BUSINESS WIRE)--May 23, 2007 - VGX Pharmaceuticals'novel pandemic influenza vaccine candidates triggered protectiveimmune respons
es in pre-clinical challenge studies, according todata presented for the first time today at the Third InternationalConference on DNA Vaccines in Malaga, Spain. VGX scientists created four synthetic consensus DNA vaccines toprotect against a leth...
Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA
Vaccine Performance; Yields Antibody Responses Comparable to
Electroporation Without Tolerability Issues
MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody respons
es than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...
CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response
Against Hepatitis B Antigen in Animals
VIENNA, Va., May 01, 2007 /PRNewswire-FirstCall/ -- CEL-SCICORPORATION announces that CEL-1000 alone increased the immunerespons
e against hepatitis B antigen, and that the combination ofCEL-1000 with MAS-1, a proprietary water-in-oil adjuvant deliverysystem owned by Mercia Pharma, induced highly significant increasesin specific anti-HBV (hepatitis B virus) antibodies. These findingswere...
Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for
Travelers' Diarrhea Stimulates Immune Response Even at Low Doses
-- Data Gathered to Assist in Design of Future Trials, OtherPrograms -- GAITHERSBURG, Md. and LISBON, Portugal, April 26, 2007/PRNewswire-FirstCall/ -- Iomai Corporation today announced resultsfrom a 400-patient, Phase 2 dose-ranging trial of its patch-basedvaccine for travelers' diarrhea. The trial was conducted to assessthe ability of a range of vaccine doses to generate an immunerespo...
Abraxis BioScience Presents Data from Pre-Clinical Study That
Provide Evidence for Chemotherapy-Induced Angiogenesis and
Rationale for Combining nab-Paclitaxel (Abraxane) with
Anti-Angiogenic Agents to Increase Tumor Response
LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, discussed results from two pre-clinical studies thatprovide evidence for chemotherapy induced angiogenesis andrationale for combining nab-paclitaxel (ABRAXANE(R) for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension) (albumin-bou...
Data Presented at AACR Meeting Show Peregrine's Bavituximab
Equivalent Can Generate Curative Immune Responses as Part of a
Vaccine-Like Regimen in Preclinical Models of Aggressive Brain
--Immunization with a Bavituximab Equivalent and Irradiated TumorCells Increased Long-Term Survival to 57% From 0% in Controls in aPreclinical Model of Brain Cancer-- LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hep...
Millennium Discovers Biomarkers Potentially Predictive of Response
to Velcade (Bortezomib) for Injection
- Findings Published in Blood Highlight Millennium Leadership inPersonalized Medicine and Could Strengthen the Role of VELCADE asFoundation of Therapy in Broad Range of Multiple Myeloma Patients - CAMBRIDGE, Mass., April 17, 2007 /PRNewswire-FirstCall/ --Findings published in the April 15th issue of Blood show that ateam of researchers led by Millennium Pharmaceuticals, Inc. hasdiscovered...
Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces
a Broad, Patient-Specific Antibody Response
SOUTH SAN FRANCISCO, Calif., April 17, 2007/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immunerespons
e data from two previously conducted Phase 2 clinical trialsof GVAX immunotherapy for prostate cancer. Evaluation of antibodyrespons
es in patients with advanced prostate cancer from thesestudies shows that the GVAX cell-based immunotherapy inducesantibody respons
es to a bro...
Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine
in Glioma Presented at American Association of Neurological
Surgeons Annual Meeting
WASHINGTON--(BUSINESS WIRE)--Apr 16, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced an oral presentation of updated datafrom a Phase 1/2 investigator-spons
ored trial of the company'sinvestigational cancer vaccine Oncophage(R) (vitespen) inrecurrent, high-grade glioma at the 75th annual meeting of theAmerican Association of Neurological Surgeons (AANS; abstract#606). Preliminary result...
New Clinical Study Results Indicate Higher Early Virologic Response
with Celgosivir Combination Therapy in HCV Non-Responders
Data to be Presented April 15th at EASL Conference in Barcelona,Spain VANCOUVER and SAN DIEGO, CA, April 11, 2007/PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developerof drugs for infectious diseases, has received new top-line resultsconfirming the previously announced clinical results (November 6,2006) indicating evidence of clinical benefit, safety andtolerability in a Phas...
Rapid Response was Crucial to Containing the 1918 Flu Pandemic
BETHESDA, Md., April 2, 2007--One of the persistent riddles of thedeadly 1918 Spanish influenza pandemic is why it struck differentcities with varying severity. Why were some municipalities such asSt. Louis spared the fate of the hard-hit cities like Philadelphiawhen both implemented similar public health measures? What made t...
New Data Show Early Non-Response to Antipsychotic Treatment May Be
Strong Predictor of Subsequent Non-Response for People with
Findings indicate early non-responders unlikely to subsequentlyrespond, have substantially more treatment costs, and may benefitfrom earlier change in treatment strategy COLORADO SPRINGS, Colo., April 03, 2007 /PRNewswire-FirstCall/-- New data presented at the 2007 International Congress onSchizophrenia Research (ICOSR) suggest that antipsychotic drugrespons
e be assessed earlier than is p...
Large Study Shows that Presence of Neutralizing Antibodies Did Not
Predict Clinical Response to Betaseron Treatment
WAYNE, N.J., April 02, 2007 /PRNewswire/ -- Berlex, Inc., a U.S.affiliate of Bayer Schering Pharma AG, Germany, announced today theresults of a retrospective study demonstrating that the presence ofneutralizing antibodies (NAbs) that can develop in respons
e toBetaseron(R) (interferon beta-1b) therapy did not predict clinicalrespons
e in patients with multiple sclerosis (MS).(1) The studyl...
Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data
Study Published in Vaccine Shows Strong Immune Respons
e, ProtectionAgainst H9N2 Influenza Strain ROCKVILLE, Md., April 02, 2007 /PRNewswire-FirstCall/ -- NovavaxInc.'s virus- like particle (VLP) vaccine triggered a robust immunerespons
e and provided protection against the H9N2 strain of avianinfluenza, according to pre- clinical data published in the onlineedition of the journal Vaccine.<...
Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting
Protective Antibody Response in Mucosal Tissues of Non-Human
Mymetics Also Announces Deal for Vaccine Delivery System NYON, Switzerland, March 29, 2007 /PRNewswire-FirstCall/ --Mymetics Corporation announced today that the Company's HIV vaccineelicited IgA mucosal antibodies in a non-human primate model.Mucosal IgA antibodies are considered a possible first line ofdefense against infection by HIV. The data were presented bySylvain Fleury, Ph.D., My...
Nventa Announces Presentation of Positive HspE7 Data from
NCI-Sponsored Clinical Trial in Cervical Dysplasia
- 78 Percent of Patients Showed Complete Respons
e or Reduction ofLesion Size by More than Fifty Percent - SAN DIEGO, CA, March 05, 2007 /PRNewswire-FirstCall/ - NventaBiopharmaceuticals Corporation today announced the presentation ofpositive results from a clinical trial examining the safety andefficacy of pilot process HspE7, an investigational therapeuticvaccine for human papillomavirus...